Can I raise a Series A before FDA clearance?

Yes, but it is harder and typically commands lower valuations. Some medtech-focused Series A funds invest in post-IDE, pre-clearance companies with compelling pivotal study data. These funds have higher risk tolerance and specifically look for opportunities to fund the clearance process. If your runway requires raising before clearance, target those specific funds rather than assuming all Series A investors will consider a pre-clearance deal.

What happens if I miss a milestone before my runway runs out?

This is one of the highest-risk scenarios in medtech. Options include bridge financing from existing investors, a down round (raising at a lower valuation than the previous round), strategic investment from a corporate VC, or in some cases, a licensing or partnership deal that brings in capital in exchange for commercial rights. The best mitigation is building runway that extends three to six months beyond when you expect to hit the milestone, to account for delays.

How should I report milestone progress to my existing investors?

Regular updates to existing investors (monthly or quarterly depending on your investor's preference) that clearly state progress against the milestones that were the basis for their investment are standard practice. These updates should be honest about delays and honest about what is driving them. Investors who are surprised by missed milestones at the next fundraise are not helpful participants in bridge financing conversations.

Do I need to have reimbursement established before Series A?

Not necessarily, but you need to have it mapped. For devices in categories with established CPT coverage for similar procedures, demonstrating that the coverage applies to your device is important. For devices in new clinical categories, a detailed reimbursement strategy developed by a qualified reimbursement consultant, with a realistic timeline and risk assessment, is expected by serious Series A investors. Treating reimbursement as someone else's problem is a red flag.

What is a Quality Management System and why does it matter for fundraising?

A Quality Management System (QMS) is the documented set of procedures, processes, and records that a medical device company must maintain to meet FDA regulatory requirements under 21 CFR Part 820, which under the Quality Management System Regulation (QMSR) incorporates ISO 13485:2016 (compliance date February 2, 2026). Having a functional, audit-ready QMS is a requirement for commercialization, not just a regulatory formality. Series A investors who conduct operational diligence ask about the QMS. A company approaching commercialization without a functional QMS will be flagged as operational risk.

Medical Device Fundraising Milestones: What to Hit Before Each Round

Direct answer: Each fundraising round in a medical device company is unlocked by a set of milestones that remove specific categories of risk. The seed round is typically unlocked by technical feasibility and regulatory pathway clarity. Series A is typically unlocked by FDA clearance or approval (for Class II devices) or compelling pivotal data (for Class III). Series B is typically unlocked by first commercial revenue and a credible reimbursement pathway. These milestones are not arbitrary: investors price rounds around risk, and each milestone removes a category of risk that was previously priced in. (As of July 2026.)

The single most effective thing a medical device founder can do to improve fundraising outcomes is to understand, ahead of each round, exactly what milestones they need to hit to make the raise viable. Running out of capital before reaching the next derisking milestone is one of the most common structural causes of medtech company failure. This article maps the milestones to the rounds so founders can plan runway accordingly.

Why Milestones Matter More Than Timelines

Many founders think about fundraising in terms of time: "We will raise our Series A in eighteen months." Investors in medtech think about it in terms of milestones: "We will fund them when they have cleared FDA and placed the device in five commercial sites."

The difference matters because milestones are what actually move valuation and investor conviction. A company that hits all of its technical and regulatory milestones but takes twenty-four months instead of eighteen is in a better fundraising position than one that holds the timeline but misses the milestones.

Building your runway plan around milestones, not just calendar time, also changes how you allocate capital. If a 510(k) submission is the milestone that unlocks your Series A, every dollar of seed capital should be evaluated against how directly it contributes to getting to submission quality.

Before the Seed Round: Milestones That Unlock Angel and Pre-Seed Capital

Angel investors and pre-seed funds in medtech are evaluating the team and the concept more than any specific technical output. But there are milestones that meaningfully improve the odds of raising pre-seed capital.

Team completeness. A founding team with at least one member who has device engineering experience and at least one with clinical domain expertise in the target indication is the minimum that experienced medtech angels look for. A regulatory affairs advisor (not necessarily a full-time hire at this stage) signals seriousness about the FDA process.

Proof of concept at bench level. Bench testing that demonstrates the core mechanism works, even in an idealized environment, is meaningful. It does not need to be production-equivalent. It needs to show that the physical principle is sound.

IP filing. A provisional patent application establishes priority on the core invention. This is not required to raise pre-seed capital but is expected by the time of a seed round, and raising pre-seed to fund the provisional filing is a legitimate use of capital.

Regulatory pathway identification. You should be able to articulate whether your device is Class I, II, or III, and which regulatory pathway you will pursue (510(k), De Novo, PMA). You do not need to have identified a predicate device for 510(k) at this stage, but you should understand the regulatory framework.

Defined clinical problem with documented unmet need. Published literature or clinical expert validation that the problem you are solving is real, significant, and not adequately addressed by existing devices.

Before the Seed Round: Milestones That Unlock Institutional Seed Capital

Institutional seed funds in medtech typically require more than pre-seed angels. The milestones that matter at this stage:

Predicate device identified (for 510(k) pathway). If you are pursuing 510(k) clearance, you should have identified the predicate device and begun building the substantial equivalence argument. This demonstrates that your regulatory strategy is not theoretical.

Pre-submission meeting scheduled or completed. The FDA's Pre-Sub program (https://www.fda.gov/medical-devices/how-study-and-market-your-device/request-feedback-and-meetings-device-questions-q-sub-program) allows companies to get written FDA feedback before submitting a formal application. Completing a pre-submission meeting, or having one scheduled with a clear question list, is a strong positive signal to institutional seed investors.

Qualified regulatory counsel engaged. Not a consultant you have had one call with, but an active regulatory counsel who knows your device and is advising on the submission strategy.

Bench or animal study data. For most Class II devices, bench testing data supporting the preliminary substantial equivalence argument. For Class III devices, early animal study data supporting the feasibility of an IDE application.

SBIR Phase I award, if applicable. Receiving an SBIR Phase I award is third-party validation that a scientific review panel found your research credible and significant. It also demonstrates non-dilutive funding discipline.

Before the Series A: Milestones That Matter

For most Class II device companies, Series A fundraising is most effective when you have reached one of the following:

510(k) clearance. Receiving substantial equivalence determination from FDA eliminates the single largest risk category in a Class II device company. Pre-clearance Series A deals happen, but they require a more experienced, risk-tolerant medtech fund and typically command lower valuations.

510(k) submission with FDA acceptance. If you cannot wait for clearance (runway is a constraint), submitting a 510(k) and receiving the FDA's acceptance letter (confirming the submission is substantively complete) is a meaningful milestone. It does not guarantee clearance but removes the submission-quality risk.

IDE approval for pivotal study (Class III pathway). For PMA-pathway devices, receiving an approved Investigational Device Exemption from FDA (https://www.fda.gov/medical-devices/how-study-and-market-your-device/investigational-device-exemption-ide) is the Series A milestone equivalent. It demonstrates that FDA has reviewed your study design and clinical evidence plan and found it acceptable.

First-in-human data (early feasibility study). For Class III devices, even if IDE approval for the pivotal study is pending, compelling early feasibility study results that demonstrate safety and initial efficacy signal are strong Series A enablers.

Commercial team in place. A VP of Sales or Chief Commercial Officer hired, or committed to join at funding, signals commercial readiness.

Reimbursement pathway mapped. A documented analysis of existing CPT coverage, or a plan for Category III tracking code and potential AMA code application, with realistic timeline and budget. Demonstrating that you have engaged a reimbursement consultant is meaningful.

The Critical But Often Overlooked Series A Milestone: Regulatory Affairs Infrastructure

Many device companies clear FDA and then immediately run into post-market surveillance obligations, Medical Device Reporting (MDR) requirements, complaint handling requirements under 21 CFR Part 803, and quality management system maintenance requirements under 21 CFR Part 820 (the Quality Management System Regulation, which as of February 2, 2026 incorporates ISO 13485:2016) that consume more regulatory affairs bandwidth than they anticipated.

Series A investors who have backed post-clearance device companies before ask about this. Do you have a regulatory affairs professional on staff, not just a consultant? Have you established your quality management system? Have you filed your 510(k) device listing and registration update (https://www.fda.gov/medical-devices/device-registration-and-listing)?

Showing up at a Series A meeting without having thought through post-market regulatory infrastructure is a credibility gap that experienced investors notice.

Before the Series B: Commercial Traction Milestones

By Series B, the device is on the market and investors are evaluating commercial execution.

Revenue. First commercial sales to unaffiliated paying customers. The amount matters less than the quality: a device placed in three top-tier academic medical centers carries more weight than the same revenue from a single customer with a personal relationship to the founder.

Reimbursement established. Payer coverage is in place, whether through an existing CPT code or through coverage determinations from major payers. Or a clear, documented timeline for reimbursement establishment.

Surgeon training program operational. For devices with a training requirement, a documented and operational training program (including proctoring model and training facility) demonstrates commercial readiness.

Repeat purchases. For disposable devices, repeat orders from initial customers demonstrate clinical adoption beyond the initial evaluation. For capital equipment, demonstrated patient throughput from installed devices.

Published clinical data. Peer-reviewed publications or presentations at major specialty society meetings that establish clinical credibility. These support both commercial adoption and the next fundraise.

Building the Milestone Roadmap Into Your Pitch

The milestone roadmap is not just for internal planning. It should be a visible part of your pitch deck and your investor conversations. Showing an investor the specific milestones your current round funds, and what state the company will be in at the end of that runway, demonstrates capital efficiency and planning discipline.

The format that works well: a simple table or timeline showing the milestone, the activity that achieves it, the capital required, and the expected timing. Then show what the company looks like at the end of that milestone: what risk has been removed, and what the next fundraise will be based on.

Connecting your milestone roadmap to your marketing strategy is also effective. At each milestone, what does your external story look like? What can you publish clinically? What claims can you make in marketing once you are cleared? Building the marketing program so it is ready to activate at clearance, not being designed from scratch after clearance, is what commercial-ready looks like.

Buzzbox Media works exclusively with medical device companies. Over 15 years, we have helped founders think through the transition from regulatory to commercial, and build the marketing infrastructure that activates when clearance arrives. If you are planning your Series A raise and want to make sure your marketing readiness is part of that story, a 30-minute call is a good starting point. Book at https://www.buzzboxmedia.com/book.